Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Quest PharmaTech Inc

Healthcare CA QPT

0.03CAD
-0.01(25.00%)

Last update at 2026-06-22T19:47:00Z

Day Range

0.030.04
LowHigh

52 Week Range

0.030.06
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap5.92M
  • Volume8728
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.81431M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Income before tax -1.80106M -3.01801M -7.33232M -85.03857M 190.06M
Minority interest - - - - 0.00000M
Net income -1.80106M -3.01801M -7.33232M -85.03857M 190.06M
Selling general administrative 0.49M 0.77M 0.50M 0.62M 0.86M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.00000M 0.00297M 0.01M 0.04M 0.04M
Ebit - - -0.83422M -0.79057M -1.07035M
Ebitda - - -7.29783M -84.98695M 190.11M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.81729M -1.31582M -0.83422M -0.79057M -1.07035M
Other operating expenses - - - - -
Interest expense 0.02M 0.02M 0.02M 0.01M 0.00777M
Tax provision 0.00000M 0.00000M - - -
Interest income - - - 0.00000M 0.00183M
Net interest income -0.02264M -0.02068M -0.02100M -0.01306M -0.00594M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.82M 1.32M 0.83M 0.79M 1.07M
Cost of revenue - - - - -
Total other income expense net -0.96113M -1.68151M -6.47710M -84.23494M 191.14M
Discontinued operations - - - - -
Net income from continuing ops -1.80106M -3.01801M -7.33232M -85.03857M 190.06M
Net income applicable to common shares - - -7.33232M -85.03857M 190.06M
Preferred stock and other adjustments - - - - -
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Total assets 22.56M 24.48M 84.36M 91.03M 175.61M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 1.17M 1.32M 1.11M 0.62M 0.39M
Total stockholder equity 21.40M 23.15M 83.25M 90.41M 175.22M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - 30.74M 30.62M 30.62M
Capital stock 30.74M 30.74M 30.74M 30.62M 30.62M
Retained earnings -20.88327M -19.08221M 41.49M 48.78M 133.81M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.01M 0.01M 0.01M
Cash 0.21M 0.72M 0.37M 0.26M 0.20M
Cash and equivalents - - - - -
Total current liabilities 1.17M 1.32M 1.11M 0.62M 0.38M
Current deferred revenue - - - - -
Net debt 0.79M 0.28M 0.63M 0.24M 0.05M
Short term debt - - - - -
Short long term debt 1.00M 1.00M 1.00M 0.50M 0.25M
Short long term debt total - - - - -
Other stockholder equity - - -0.11449M -0.05033M -
Property plant equipment - - 0.00297M 0.02M 0.06M
Total current assets 0.23M 0.84M 0.62M 0.29M 0.28M
Long term investments 22.33M 23.63M 83.72M 90.71M 175.27M
Net tangible assets - - 83.25M 90.41M 175.22M
Short term investments - - - - 0.00000M
Net receivables - - 0.22M 0.00032M 0.03M
Long term debt - - - - -
Inventory - - - - -
Accounts payable - - 0.11M 0.11M 0.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 22.34M 23.64M 83.74M 90.74M 175.33M
Capital lease obligations - - 0.00000M 0.01M 0.05M
Long term debt total - - - - -
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Investments 0.00000M 0.00000M -0.01400M -0.01400M 0.30M
Change to liabilities - - 0.00000M 0.02M -0.00148M
Total cashflows from investing activities - - -0.01400M -0.01400M 0.26M
Net borrowings 0.00000M 0.00000M 0.50M 0.25M 0.25M
Total cash from financing activities 0.00000M 0.68M 0.68M 0.25M 0.30M
Change to operating activities - - -0.22523M 0.03M -0.02894M
Net income -1.80106M -3.01801M -7.33232M -85.03857M 190.06M
Change in cash -0.51188M 0.34M 0.11M 0.07M -1.95407M
Begin period cash flow 0.72M 0.37M 0.26M 0.20M 2.15M
End period cash flow 0.21M 0.72M 0.37M 0.26M 0.20M
Total cash from operating activities -0.51188M -0.34242M -0.55468M -0.17078M -2.51503M
Issuance of capital stock - 0.00000M 0.09M 0.00000M -
Depreciation 0.00000M 0.00297M 0.01M 0.04M 0.04M
Other cashflows from investing activities - - -0.01400M -0.01400M -0.03804M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.03M -0.02180M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - 6.99M 84.75M -192.56658M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.15606M 0.25M -0.22523M 0.08M -0.05222M
Stock based compensation 0.08M 0.47M 0.15M 0.27M 0.45M
Other non cash items - - - - -13.54250M
Free cash flow -0.51188M -0.34242M -0.55468M -0.17078M -2.55307M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
QPT
Quest PharmaTech Inc		 -0.01 25.00% 0.03 - - 515.97 0.26 331.55 -0.1576
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Quest PharmaTech Inc

97 Street NW, Edmonton, AB, Canada, T6E 5R9

Key Executives

Name Title Year Born
Dr. Ragupathy Madiyalakan Ph.D. CEO & Director NA
Mr. Pierre Vermette Chief Financial Officer NA
Mr. Roger Andrews Head of Investor Relations & Corp. Communications NA
Mr. Douglas C. Bachman VP of Corp. Devel. 1954
Mr. Thomas Woo VP of Product Devel. NA
Mr. Pierre Vermette C.A., CPA Chief Financial Officer NA
Mr. Roger Andrews Head of Investor Relations & Corporate Communications NA
Mr. Douglas C. Bachman Vice President of Corporate Development 1954
Mr. Thomas Woo Vice President of Product Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.